Sökning: WFRF:(Engelborghs Sebastiaan)
> (2010-2014) >
Diagnosis-Independe...
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
-
De Meyer, Geert (författare)
-
Shapiro, Fred (författare)
-
Vanderstichele, Hugo (författare)
-
visa fler...
-
Vanmechelen, Eugeen (författare)
-
Engelborghs, Sebastiaan (författare)
-
De Deyn, Peter Paul (författare)
-
Coart, Els (författare)
-
- Hansson, Oskar (författare)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
-
- Minthon, Lennart (författare)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
-
Zetterberg, Henrik (författare)
-
Blennow, Kaj (författare)
-
Shaw, Leslie (författare)
-
Trojanowski, John Q. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2010
- 2010
- Engelska.
-
Ingår i: Archives of Neurology. - 0003-9942. ; 67:8, s. 949-956
- Relaterad länk:
-
http://archneur.ama-...
-
visa fler...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To identify biomarker patterns typical for Alzheimer disease (AD) in an independent, unsupervised way, without using information on the clinical diagnosis. Design: Mixture modeling approach. Setting: Alzheimer's Disease Neuroimaging Initiative database. Patients or Other Participants: Cognitively normal persons, patients with AD, and individuals with mild cognitive impairment. Main Outcome Measures: Cerebrospinal fluid derived p-amyloid protein 1-42, total tau protein, and phosphorylated tau(181p) protein concentrations were used as biomarkers on a clinically well-characterized data set. The outcome of the qualification analysis was validated on 2 additional data sets, 1 of which was autopsy confirmed. Results: Using the US Alzheimer's Disease Neuroimaging Initiative data set, a cerebrospinal fluid beta-amyloid protein 1-42/phosphorylated tau(181P) biomarker mixture model identified 1 feature linked to AD, while the other matched the "healthy" status. The AD signature was found in 90%, 72%, and 36% of patients in the AD, mild cognitive impairment, and cognitively normal groups, respectively. The cognitively normal group with the AD signature was enriched in apolipoprotein E 64 allele carriers. Results were validated on 2 other data sets. In 1 study consisting of 68 autopsy-confirmed AD cases, 64 of 68 patients (94% sensitivity) were correctly classified with the AD feature. In another. data set with patients (n=57) with mild cognitive impairment followed up for 5 years, the model showed a sensitivity of 100% in patients progressing to AD. Conclusions: The mixture modeling approach, totally independent of clinical AD diagnosis, correctly classified patients with AD. The unexpected presence of the AD signature in more than one-third of cognitively normal subjects suggests that AD pathology is active and detectable earlier than has heretofore been envisioned.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
De Meyer, Geert
-
Shapiro, Fred
-
Vanderstichele, ...
-
Vanmechelen, Eug ...
-
Engelborghs, Seb ...
-
De Deyn, Peter P ...
-
visa fler...
-
Coart, Els
-
Hansson, Oskar
-
Minthon, Lennart
-
Zetterberg, Henr ...
-
Blennow, Kaj
-
Shaw, Leslie
-
Trojanowski, Joh ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Archives of Neur ...
- Av lärosätet
-
Lunds universitet